|
MechanismIL-11RA antagonists |
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismIL-18BP modulators |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismIL-11 modulators |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Active, not recruitingPhase 2 A Phase 2, Proof-of-Concept, Randomized, Double-Masked, Placebo-Controlled Study to Determine the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for treatment of patients with thyroid eye disease (TED).
The primary and secondary objectives of this study are to evaluate the safety, efficacy, and pharmacokinetics of LASN01 administered IV in patients with TED with no prior anti-IGF-1R treatment or in patients with TED who have previously received teprotumumab treatment.
100 Clinical Results associated with Lassen Therapeutics 1, Inc.
0 Patents (Medical) associated with Lassen Therapeutics 1, Inc.
100 Deals associated with Lassen Therapeutics 1, Inc.
100 Translational Medicine associated with Lassen Therapeutics 1, Inc.